Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 19, 2014

Primary Completion Date

June 17, 2021

Study Completion Date

June 17, 2021

Conditions

Recurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Cytarabine

Given IV

BIOLOGICAL

Filgrastim

Given SC

BIOLOGICAL

Filgrastim-sndz

Given SC

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01787474 - Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter